Dr. John Cush RheumNow
2 years 4 months ago
Review of 31 FDA Rheum drug approvals betw 1995-2021 showed patient-reported outcomes seldom reported or published. Despite meeting MCID (57%) & significance (85%), 1/3 PROs not reported & 10% remained unpublished (4yrs later) https://t.co/pvGhTxlP03 https://t.co/t3VEHw7FJv
Dr. John Cush RheumNow
2 years 4 months ago
FDA has approved upadacitinib (Rinvoq), for use in pediatric patients (age >2 years) w/ active polyarticular juvenile idiopathic arthritis (pJIA) & psoriatic arthritis (PsA), after inadequate resp/intolerance to TNFi. Also available as oral solution. https://t.co/lGvIHb8wfZ https://t.co/8BiTnTNJzO
A EULAR consensus group has established classification criteria for overall hand osteoarthritis (OA) and its subtypes (interphalangeal OA and thumb base OA).The criteria require two mandatory criteria to be met:must have symptoms (pain, aching and/or stiffness) in at least one target joint on most days of the previous 6 weeks.
Dr. John Cush RheumNow
2 years 4 months ago
Review of the Scleroderma spectrum disorders (full-read) https://t.co/xaIxf8q0Tj https://t.co/kxFiQTqKqV
Dr. John Cush RheumNow
2 years 4 months ago
Boxed Warnings in Derm:
- Topical Calcineurin inhib (atopic dermatitis): rare risk of cancer
- IL-17 Inhibitors (PSO, PsA): exacerbation of IBD (38 RCTs: only 12/16,690 new IBD case
- Psoriasis and suicidality: suicide risk same w/ or without treatments https://t.co/HsjO78NtjP https://t.co/v9Pys8RwcH
The American College of Rheumatology has submitted its response to the Centers for Medicare & Medicaid Services (CMS) request for information and feedback from stakeholders on how best to enhance Medicare Advantage data capabilities and increase public transparency.
Dr. John Cush RheumNow
2 years 4 months ago
Cohort study of 25 315 women followed 25 years shows adherence to the Mediterranean diet associated with a 23% reduced all-cause mortality - explained by lipids, inflammation markers and BMI; more than cholesterol or glycemic measures https://t.co/kgj18lG12G https://t.co/NN2FlPSngW
Dr. John Cush RheumNow
2 years 4 months ago
TriNetX US claims study of 7580 RA pts Rx w/ tofacitinib or adalimumab found Tofa signif. more likely to cause dyslipidemia (HR 1.250), but no difference betw TOFA & ADA in MACE (HR 0.995; 0.76–1.3) or all-cause mortality (HR 1.4; 0.89–2.2) https://t.co/83CGng2R9e https://t.co/QfD4ePuTER
Dr. John Cush RheumNow
2 years 4 months ago
ACR’s Run at Goliath (PCPs) (5.31.2024)
The ACR (and Cush) address their new website designed to educate PCPs and APPs - what do you think?
https://t.co/DQOkhowU0b https://t.co/MK9aVe7Yaf
Dr. John Cush RheumNow
2 years 4 months ago
We are covering #EULAR24! We'll be sharing recaps, videos, and more.
https://t.co/7ehREq5gnl https://t.co/ao2LzcFxrt
Dr. John Cush RheumNow
2 years 4 months ago
Full read review on Psoriasis Flares; risks:
- mechanical stress
- infections
-dysbiosis
-drugs (Lithium, B-blockers, HCQ, tetracyclines, ACEi, IFN)
- environment(smoking, obesity)
-lifestyle
- stress
- hormonal/metabolic https://t.co/dpnVS05Pm7 https://t.co/l3rdxaBSgV
Dr. John Cush RheumNow
2 years 4 months ago
NEJM Images - Polyarteritis Nodosa. 62 yoM with myalgias, wt loss, numbness, negative ANCA & HBV. Abdominal angiography shows multiple aneurysms. https://t.co/Axaobo01wD https://t.co/y2XYg6kVjB
Diet has long been influential in gout care and risks. A large cohort study has shown that plant-based diets may reduce the risk of developing gout.
This prospective study assessed the risk of developing incident gout based on consumption of healthy and unhealthy plant-based diets.
Dr. John Cush RheumNow
2 years 4 months ago
Forbes on the future of CAR-T cell therapy - A Gamechanger For Autoimmune Diseases. Innovation, costs, more trials and regulatory differences for autoimmune (vs cancer) patietns? https://t.co/6Siv0Y1GDB https://t.co/Mmbh4ER7vf https://t.co/j8bgn8DkLw
Dr. John Cush RheumNow
2 years 4 months ago
Colchicine prophylaxis w/ allopurinol (“start-low go-slow” 100mg escalation strategy), is best used in pts w/ gout flare in month prior to allopurinol. Longer prophylaxis may be required w/ ongoing flares in 1st 6mos of allopurinol if T2T not achieved https://t.co/yupiq26BJA https://t.co/KDF394SC30
